+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 70Years
FEMALE
ID07876154

Study of IparomlimabTuvonralimab Combined With Nab-paclitaxel and Cisplatin Before Surgery for Locally Advanced Cervical Cancer

Led by Xijing Hospital · Updated on 2026-10-15

34

Participants Needed

1

Research Sites

48 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to find out if a combination of IparomlimabTuvonralimab with nab-paclitaxel and cisplatin can treat locally advanced cervical cancer in adult female patients. It focuses on assessing the pathological complete response rate after this neoadjuvant treatment and also monitors objective response rate, progression-free survival, overall survival, and changes in tumor immune environment and biomarkers. This is a single-arm trial without a comparison group. Participants receive three cycles of intravenous IparomlimabTuvonralimab at 5 mgkg, nab-paclitaxel at 260 mgm2, and cisplatin at 75 mgm2 every three weeks. If cisplatin is not tolerated, carboplatin may be used instead. After the neoadjuvant therapy, participants undergo radical surgery. Throughout the study, scheduled imaging, blood tests, and tissue biomarker assessments are performed. During the trial, participants will have regular follow-up visits to monitor survival and safety. Researchers evaluate the pathological complete response within two weeks after surgery and measure objective response after the three treatment cycles. They also track progression-free and overall survival for up to 36 months post-surgery, as well as treatment-related side effects and changes in immune biomarkers at baseline, before surgery, and immediately after surgery. The study lasts until June 2028.

CONDITIONS

Brief Title

Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer

Research Team

S

Shujuan Liu, MD

X

Xiaohui Lv, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here